Clinical observation on Bacteroides fragilis (BF839) reducing bone marrow suppression after chemotherapy in patients with lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022439

Enrollment

Unknown

Registered

2019-04-11

Start date

2019-04-10

Completion date

Unknown

Last updated

2019-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Control group:chemotherapy

Intervention group:Bacteroides fragilis (BF839) + chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with lung cancer by histological or cytological diagnosis and preparing for the first chemotherapy; (2) Aged 18 to 75 years; (3) Expected survival time> 3 months; (4) No history of allergy probiotic preparations; (5) Subjects have agreed to and signed informed consent prior to participation in the study.

Exclusion criteria

Exclusion criteria: 1) Cases of simultaneous radiotherapy (including internal radionuclide); 2) Those who have participated in other clinical trials in the past 1 month; 3) The investigator believes that others are not suitable for the trial.

Design outcomes

Primary

Measure	Time frame
Blood routine;Post-chemotherapy side-effect rating;Proportion of G-CSF injection;	—

Secondary

Measure	Time frame
weight;	—

Countries

China

Contacts

Public ContactYang Jun

yangjun9909@126.com+86 020-34152267

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026